Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocr...

Full description

Saved in:
Bibliographic Details
Main Authors: Binghe Xu (Author), Qingyuan Zhang (Author), Xichun Hu (Author), Qing Li (Author), Tao Sun (Author), Wei Li (Author), Quchang Ouyang (Author), Jingfen Wang (Author), Zhongsheng Tong (Author), Min Yan (Author), Huiping Li (Author), Xiaohua Zeng (Author), Changping Shan (Author), Xian Wang (Author), Xi Yan (Author), Jian Zhang (Author), Yue Zhang (Author), Jiani Wang (Author), Liang Zhang (Author), Ying Lin (Author), Jifeng Feng (Author), Qianjun Chen (Author), Jian Huang (Author), Lu Zhang (Author), Lisong Yang (Author), Ying Tian (Author), Hongyan Shang (Author)
Format: Book
Published: Elsevier, 2023-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available